Literature DB >> 24285371

RGD-based PET tracers for imaging receptor integrin αv β3 expression.

Hancheng Cai1, Peter S Conti.   

Abstract

Positron emission tomography (PET) imaging of receptor integrin αv β3 expression may play a key role in the early detection of cancer and cardiovascular diseases, monitoring disease progression, evaluating therapeutic response, and aiding anti-angiogenic drugs discovery and development. The last decade has seen the development of new PET tracers for in vivo imaging of integrin αv β3 expression along with advances in PET chemistry. In this review, we will focus on the radiochemistry development of PET tracers based on arginine-glycine-aspartic acid (RGD) peptide, present an overview of general strategies for preparing RGD-based PET tracers, and review the recent advances in preparations of (18) F-labeled, (64) Cu-labeled, and (68) Ga-labeled RGD tracers, RGD-based PET multivalent probes, and RGD-based PET multimodality probes for imaging receptor integrin αv β3 expression.
Copyright © 2013 John Wiley & Sons, Ltd.

Entities:  

Keywords:  PET imaging; RGD; integrin; radiochemistry

Mesh:

Substances:

Year:  2013        PMID: 24285371     DOI: 10.1002/jlcr.2999

Source DB:  PubMed          Journal:  J Labelled Comp Radiopharm        ISSN: 0362-4803            Impact factor:   1.921


  23 in total

Review 1.  18 F-Labeling of Sensitive Biomolecules for Positron Emission Tomography.

Authors:  Hema S Krishnan; Longle Ma; Neil Vasdev; Steven H Liang
Journal:  Chemistry       Date:  2017-09-01       Impact factor: 5.236

Review 2.  Peptide-based imaging agents for cancer detection.

Authors:  Xiaolian Sun; Yesen Li; Ting Liu; Zijing Li; Xianzhong Zhang; Xiaoyuan Chen
Journal:  Adv Drug Deliv Rev       Date:  2016-06-18       Impact factor: 15.470

3.  68Gallium-Arginine-Glycine-Aspartic Acid and 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Chondroblastic Osteosarcoma of the Skull.

Authors:  Akintunde Orunmuyi; Moshe Modiselle; Thabo Lengana; Thomas Ebenhan; Mariza Vorster; Mike Sathekge
Journal:  Nucl Med Mol Imaging       Date:  2016-02-12

4.  Preparation and evaluation of a 68Ga-labeled RGD-containing octapeptide for noninvasive imaging of angiogenesis: biodistribution in non-human primate.

Authors:  Irina Velikyan; Örjan Lindhe
Journal:  Am J Nucl Med Mol Imaging       Date:  2018-02-05

5.  (18)F-Alfatide II PET/CT in healthy human volunteers and patients with brain metastases.

Authors:  Chunjing Yu; Donghui Pan; Baoming Mi; Yuping Xu; Lixin Lang; Gang Niu; Min Yang; Weixing Wan; Xiaoyuan Chen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-07-01       Impact factor: 9.236

6.  Synthesis and 18F-radiolabeling of thymidine AMBF3 conjugates.

Authors:  Antonio A W L Wong; Jerome Lozada; Mathieu L Lepage; Chengcheng Zhang; Helen Merkens; Jutta Zeisler; Kuo-Shyan Lin; François Bénard; David M Perrin
Journal:  RSC Med Chem       Date:  2020-04-23

Review 7.  Fluorine-18: Radiochemistry and Target-Specific PET Molecular Probes Design.

Authors:  Yunze Wang; Qingyu Lin; Hongcheng Shi; Dengfeng Cheng
Journal:  Front Chem       Date:  2022-06-29       Impact factor: 5.545

8.  68Ga-Chelation and comparative evaluation of N,N'-bis-[2-hydroxy-5-(carboxyethyl)benzyl]ethylenediamine-N,N'-diacetic acid (HBED-CC) conjugated NGR and RGD peptides as tumor targeted molecular imaging probes.

Authors:  Drishty Satpati; Rohit Sharma; Chandan Kumar; Haladhar Dev Sarma; Ashutosh Dash
Journal:  Medchemcomm       Date:  2017-02-16       Impact factor: 3.597

9.  A Systematic Comparative Evaluation of 68Ga-Labeled RGD Peptides Conjugated with Different Chelators.

Authors:  Akanksha Jain; Sudipta Chakraborty; H D Sarma; Ashutosh Dash
Journal:  Nucl Med Mol Imaging       Date:  2017-12-05

10.  Nucleophilic (Radio)Fluorination of α-Diazocarbonyl Compounds Enabled by Copper-Catalyzed H-F Insertion.

Authors:  Erin E Gray; Matthew K Nielsen; Kimberly A Choquette; Julia A Kalow; Thomas J A Graham; Abigail G Doyle
Journal:  J Am Chem Soc       Date:  2016-08-17       Impact factor: 15.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.